Skip Navigation LinksHome > March 2012 - Volume 19 - Issue 2 > New induction and postinduction strategies in acute myeloid...
Current Opinion in Hematology:
doi: 10.1097/MOH.0b013e3283500a92
MYELOID DISEASE: Edited by Martin S. Tallman

New induction and postinduction strategies in acute myeloid leukemia

Burnett, Alan K.

Collapse Box


Purpose of review: Improving or replacing the traditional induction (3 + 7) and consolidation (high-dose cytarabine; Ara-C) as the standard of care for acute myeloid leukemia (AML) has proved disappointing.

Recent findings: Recent studies have raised the possibility that daunorubicin dose escalation might have the potential to improve survival. Antibody-directed therapy by means of gemtuzumab ozogamicin as an adjunct to induction chemotherapy may yet be a viable option in older patients, and alternative nucleoside analogues in induction could help higher risk subgroups. In consolidation, the number of courses and dose level of Ara-C required are being clarified. New treatments for older patients who will not be subjected to conventional chemotherapy are an active area, but randomized trials have not yet usurped low-dose Ara-C (LDAC).

Summary: Recent information in these areas is reviewed.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.